Case Summary:

In the case of Teva Pharmaceuticals USA, Inc. v. Eli Lilly and Company (Docket No. 25-2125), argued before the U.S. Court of Appeals for the Seventh Circuit on February 11, 2026, the relevant facts are as follows:

The litigation centers on a breach of contract claim involving a 2018 settlement agreement between Teva and Eli Lilly regarding the osteoporosis drug Forteo (teriparatide).

Under the terms of the 2018 settlement, Eli Lilly provided covenants not to sue and agreed to waive certain exclusivity rights to allow Teva to market a generic version of the drug.

The factual dispute arose in 2019 after Eli Lilly's primary patents for Forteo expired, but the company subsequently obtained a new three-year regulatory exclusivity period ...